Is MDXH or NEO more undervalued in 2026?

CirclFi compares MDxHealth SA (MDXH) and NeoGenomics, Inc. (NEO) using 13 institutional-grade valuation models. MDXH has a Quality of Company score of 1.7/10 while NEO scores 6.8/10.

Which is a better buy — MDXH or NEO?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do MDXH and NEO valuations compare?

MDXH at $0.75 and NEO at $10.19 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

MDXH vs NEO Valuation Comparison 2026 — Intrinsic Value Analysis

MDXH

Diagnostics & Research

MDxHealth SA

Quality

1.7

out of 10

Value Trap

—

Price

$0.75

Last close

Models

8/13

Active

NEO

Diagnostics & Research

NeoGenomics, Inc.

Quality

6.8

out of 10

Value Trap

LOW

Price

$10.19

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	MDXH Fair Value	MDXH Upside	NEO Fair Value	NEO Upside
Bayesian DCF	Intrinsic	$0.20	-73.5%	$0.46	-95.5%
Earnings Power Value	Intrinsic	—	—	$5.57	-41.0%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$2.01	+167.8%	$10.32	+1.3%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for MDXH vs NEO — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

MDXH vs NEO — Which Stock Is More Undervalued?

NEO scores higher with a 6.8/10 quality rating vs MDXH's 1.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing MDxHealth SA (MDXH) and NeoGenomics, Inc. (NEO) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

MDXH currently trades at $0.75 with a QOC of 1.7/10, while NEO trades at $10.19 with a QOC of 6.8/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).